Increased therapeutic efficacy of combination of azithromycin and ceftazidime on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection.
Increased therapeutic efficacy of combination of azithromycin and ceftazidime on Pseudomonas aeruginosa biofilm in an animal model of ureteral stent infection.
复制标题
阿奇霉素联合头孢他啶联合治疗输尿管支架感染动物模型中铜绿假单胞菌生物膜的疗效
DOI：
10.1186/s12866-016-0744-1
复制
发表时间：
2016-06-24
期刊：
影响因子：
4.2
通讯作者：
Chen J
中科院分区：
文献类型：
--
作者：
Wang X;Cai Y;Xing H;Wu W;Wang G;Li L;Chen J
背景输尿管支架置入引起的感染是最困难的医学问题之一，因为一旦细菌驻留在生物膜中，它们就对抗生素以及宿主的免疫防御具有极强的抵抗力。在这项研究中，我们评估了阿奇霉素和头孢他啶在体外和体内预防铜绿假单胞菌输尿管支架感染的有效性。结果粘附细菌的药敏试验表明，阿奇霉素治疗强烈抑制了生物膜，在阿奇霉素存在下，头孢他啶对粘附细菌的最小抑菌浓度（MIC）和最小杀菌浓度（MBC）显著低于在没有阿奇霉素的情况下获得的那些。此外，头孢他啶加阿奇霉素减少抽搐运动和生产的鼠李糖脂。单药治疗组中，头孢他啶体内静脉注射对细菌负荷的抑制作用最强。阿奇霉素预防性注射联合头孢他啶对细菌载量的抑制作用比每种单一抗生素都要高。结论这种联合治疗方案有可能有助于临床环境中假单胞菌生物被膜的成功消除。
BackgroundInfection caused by ureteral stent indwelling is one of the most difficult medical problems, since once bacteria reside in biofilms they are extremely resistant to antibiotics as well as to the host immune defences. In this study we assessed the in vitro and in vivo efficacy of azithromycin and ceftazidime in preventing ureteral stent infection by Pseudomonas aeruginosa.ResultsThe susceptibility testing with adherent bacteria showed that the biofilm was strongly inhibited by azithromycin treatment, ceftazidime against adherent bacteria in the presence of azithromycin showed the minimum inhibitory concentrations (MICs) and minimum bacteriocidal concentrations (MBCs) dramatically lower than those obtained in the absence of azithromycin. Moreover, ceftazidime plus azithromycin reduced twitching motility and production of rhamnolipid. For the single-treatment groups, in vivo intravenous injection of ceftazidime showed the highest inhibitory effect on bacterial load. Azithromycin prophylactic injection combined with ceftazidime showed increased inhibitory effect on bacterial load than that of each single antibiotic.Conclusions This combined treatment option have the potential to contribute to the success of Pseudomonas biofilm elimination in the clinical environment.